A Study of Seltorexant in Participants With Probable Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

November 10, 2023

Study Completion Date

November 10, 2023

Conditions
Alzheimer Disease
Interventions
DRUG

Seltorexant

Seltorexant 20 mg will be administered orally as a tablet.

DRUG

Placebo

Matching placebo will be administered orally as a tablet.

Trial Locations (25)

10312

Richmond Behavioral Associates, Staten Island

30315

Sonar Clinical Research, Atlanta

30328

NeuroTrials Research Inc, Atlanta

30331

Atlanta Center for Medical Research, Atlanta

33030

Luminous Clinical Research, Homestead

33125

Global Medical Institutes, Miami

33135

Office of Emilio Mantero-Atienza, MD, Miami

33155

Quantix Research, Miami

33156

Entrust Clinical Research, Miami

33166

South Florida Research Center Inc., Miami Springs

33173

Florida International Research Center (FIRC), Miami

33175

P&S Research, LLC, Miami

33176

IMIC Inc, Miami

33184

Biovision Medical, Miami

33777

Accel Clinical Research, Seminole

34239

Intercoastal Medical Group, Sarasota

37232

Vanderbilt University Medical Center, Nashville

70121

Ochsner Medical Center, New Orleans

77429

Gill Neuroscience, Cypress

84107

Wasatch Clinical Research, Salt Lake City

85283

Medical Advancement Center of Arizona, Tempe

94549

Sunwise Clinical Research, Lafayette

33155-4630

Allied Biomedical Research Institute (ABRI), Inc, Miami

02131

Boston Clinical Trials, Boston

05201

Memory Clinic Inc, Bennington

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY